Facts about asthma:

  • 26 million people in the US currently suffer from asthma
  • 10.7 million of patients with asthma have reported having at least one asthma attack in the past year
  • Asthma costs $56 billion every year in medicine, hospitalizations, missed school days, and missed work days
  • There are 15.3 million hospital visits for asthma annually
  • Asthma is responsible for 1.8 million emergency room visits every year 
  • Uncontrolled asthma costs $14,212 to manage annually
  • Controlled asthma costs $6,452 to manage annually
  • Asthma is the leading cause of student absences at a rate of 10.5 million days a year

Benefits of careful management:

  • Fewer emergency room visits
  • Fewer asthma-related hospitalizations
  • Improved school and work attendance 
  • Improved patient satisfaction and productivity

Asthma is considered the most common chronic illness among both children and adults. The U.S. Department of Health and Human Services declared asthma an epidemic 15 years ago and has been working tirelessly to reduce asthma rates and costs. However, rates of asthma have only increased and healthcare costs have skyrocketed. The failure to reduce asthma rates can be attributed to its difficulty to manage and the lack of inexpensive and reliable methods to manage asthma. Mismanagement has resulted in increased rates of severe and uncontrolled asthma responsible for 80% of the costs associated with asthma management. 

Current National Institutes of Health (NIH) guidelines dictate asthma should be diagnosed early and treated aggressively before a case of mild asthma progresses to severe asthma with a much higher risk of asthma attacks and significantly higher treatment costs. Asthma cannot be cured, but it can be controlled to afford patients a life without restrictions. Despite a clear plan of action, compliance rates with NIH guidelines remain unsatisfactory, likely due to patients refusing to regularly perform the uncomfortable and sometimes complex methods currently prescribed for asthma monitoring. 

BioLum plans to address these issues by providing a simple and effective method to monitor asthma symptoms and airway inflammation. Instead of having to visit the doctor's office for an uncomfortable spirometry test or collecting unreliable data with an at-home peak flow meter test, patients can use our 30 second assay to quantify the levels of airway inflammation in real time. By relying on direct biological data instead of subjective self-reported patient data, physicians can make personalized healthcare decisions for each patient and monitor the effectiveness of the treatment based on daily changes of a patient's airway inflammation.